CN116966307A - Ampk抑制剂联合hdac抑制剂在制备肿瘤治疗的药物中的应用 - Google Patents
Ampk抑制剂联合hdac抑制剂在制备肿瘤治疗的药物中的应用 Download PDFInfo
- Publication number
- CN116966307A CN116966307A CN202210429195.6A CN202210429195A CN116966307A CN 116966307 A CN116966307 A CN 116966307A CN 202210429195 A CN202210429195 A CN 202210429195A CN 116966307 A CN116966307 A CN 116966307A
- Authority
- CN
- China
- Prior art keywords
- ampk
- inhibitor
- tumor
- hdac inhibitor
- hdac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003276 histone deacetylase inhibitor Substances 0.000 title claims abstract description 42
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title claims abstract description 41
- 239000003112 inhibitor Substances 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 title claims abstract 13
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 title claims abstract 13
- 238000002360 preparation method Methods 0.000 title claims description 6
- 206010028980 Neoplasm Diseases 0.000 title abstract description 35
- 229940079593 drug Drugs 0.000 title description 6
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 14
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 13
- QTCSXAUJBQZZSN-UHFFFAOYSA-N n-[2-methyl-2-(2-phenyl-1,3-oxazol-4-yl)propyl]-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide Chemical compound C=1OC(C=2C=CC=CC=2)=NC=1C(C)(C)CNC(=O)C(C=1)=CC=CC=1C1=NOC(C(F)(F)F)=N1 QTCSXAUJBQZZSN-UHFFFAOYSA-N 0.000 claims abstract description 10
- HORXBWNTEDOVKN-UHFFFAOYSA-N n-[[4-(4-phenyl-1,3-thiazol-2-yl)oxan-4-yl]methyl]-3-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide Chemical compound O1C(C(F)(F)F)=NC(C=2C=C(C=CC=2)C(=O)NCC2(CCOCC2)C=2SC=C(N=2)C=2C=CC=CC=2)=N1 HORXBWNTEDOVKN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 230000030833 cell death Effects 0.000 claims description 13
- 230000014509 gene expression Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- 101100321932 Rattus norvegicus Prkaa2 gene Proteins 0.000 claims description 2
- 230000030279 gene silencing Effects 0.000 claims description 2
- 238000012226 gene silencing method Methods 0.000 claims description 2
- 238000010362 genome editing Methods 0.000 claims description 2
- 229940126586 small molecule drug Drugs 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 230000034994 death Effects 0.000 abstract description 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 42
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 20
- 201000011510 cancer Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 102000003964 Histone deacetylase Human genes 0.000 description 4
- 108090000353 Histone deacetylase Proteins 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 241001529936 Murinae Species 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006609 metabolic stress Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 108700038202 AMP-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100326341 Drosophila melanogaster brun gene Proteins 0.000 description 1
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 description 1
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 1
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 108010026668 snake venom protein C activator Proteins 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
AMPK抑制剂联合HDAC抑制剂在制备肿瘤治疗的药物中的应用，属于抗肿瘤药物技术领域。本发明提供了AMPK抑制剂联合HDAC抑制剂在制备治疗肿瘤疾病的药物中的应用。所述AMPK抑制剂包括Compound C。所述HDAC抑制剂包括HDAC inhibitor、HDACi、TMP195、TMP269。一种抗肿瘤药物组合物，包含AMPK抑制剂和HDAC抑制剂。AMPK抑制剂与HDAC抑制剂组合物能够显著促进肿瘤细胞死亡，为临床肿瘤治疗提供了新的潜力方案。
Description
技术领域
本发明属于抗肿瘤药物技术领域，具体涉及AMPK抑制剂联合HDAC抑制剂在制备肿瘤治疗的药物中的应用。
背景技术
肿瘤(tumor，neoplasm)是一种非遗传的基因病。正常细胞在致瘤因素作用下，基因发生了改变，失去对其生长的正常调控，导致异常增生。肿瘤细胞有三个显著的基本特征即：不死性，迁移性和失去接触抑制。肿瘤治疗的核心思想就是杀死、清除肿瘤细胞。目前临床上常用的肿瘤治疗手段如化疗、放疗、激素治疗、分子靶向治疗、免疫治疗等。但是几乎所有的药物，随着患者使用时间的推移，癌细胞都会对药物产生抗性，使得药物对癌细胞的作用停止。肿瘤细胞对药物治疗的这种获得性抵抗力不仅严重限制了临床治疗的效果，同时也是肿瘤复发的分子基础。因此，我们需要开发新的治疗方法或优化已有的方法，一方面可以打破耐药、增强抗肿瘤效果，另一方面可以丰富我们对抗肿瘤的“武器库”，拓宽肿瘤治疗策略的选择范围。
组蛋白去乙酰化酶(Histone deacetylases，HDACs)是一个关键的基因表达调控因子，通过去除组蛋白乙酰化修饰抑制基因转录。在多数肿瘤中都观察到HDACs的异常表达，是肿瘤治疗的潜力靶点。靶向HDCA的抑制剂(HDACi)已被FDA批准用于皮肤T淋巴瘤(Cutaneous T-cell lymphoma)以及多发性骨髓瘤(Multiple myeloma)等肿瘤的治疗。尽管被寄予厚望，但临床疗效差强人意，耐药时有发生。而在实体瘤治疗方面，有多项临床实验正在开展，但截至目前，尚未有成功的案例(参考文献：Amila Suraweera,Kenneth J.O’Byrne and Derek J. Richard.Combination Therapy with Histone Deacetylaseinhibitors(HDACi)for the Treatment of Cancer:Achieving the Full TherapeuticPotential ofHDACi.Frontiers in oncology.2018March 29: doi:10.3389/fonc.2018.00092)。因此，临床上急需一些能够打破该药耐药性或者增强其抗实体瘤效果的方法。
腺苷酸活化蛋白激酶(AMPK)是细胞的能量和营养感受器，对细胞能量稳态以及代谢调控中起关键性作用。传统观点认为，正常情况下AMPK是一个肿瘤抑制因子，在癌症发展初期，可以通过代谢调控或者磷酸化介导肿瘤抑制因子TET2、p53、TSC2等抑制肿瘤生长。然而近年来，越来越多的研究发现在一些特殊的基因状态或代谢压力条件下(如缺氧、营养匮乏等)，AMPK在肿瘤细胞中表达上调或者活化增强。对于这部分肿瘤，AMPK通过一系列保护机制帮助肿瘤细胞应对生存压力，如降低能量消耗，延缓生长，增加血管生成和抑制炎症反应等，这可能是肿瘤在恶劣条件下继续存活的重要原因之一(参考文献：Faubert B,Vincent EE,Poffenberger MC,Jones RG.The AMP-activated protein kinase(AMPK)andcancer: many faces ofa metabolic regulator.Cancer Lett.2015Jan 28；356(2Pt A):165-70.)。研究发现 AMPK在原位移植的乳腺肿瘤中被证明是通过调节肿瘤细胞的氧化还原状态来延长细胞存活的(参考文献S.M.Jeon,N.S.Chandel,N.Hay.AMPKregulates NADPHhomeostasis to promote tumour cell survival during energy stress.Nature,485(2012),pp.661-665)。此外，在三种不同的小鼠白血病模型：急性髓系白血病(AML)、急性淋巴细胞白血病(ALL)、急性T淋巴细胞白血病(T-ALL)中，AMPK基因缺失导致肿瘤细胞死亡，并显著提高了小鼠白血病的存活率(参考文献Eichner LJ,Brun SN.Genetic analysisreveals AMPK is required to support tumor growth in Murine Kras-DependentLung Cancer Models.Cell Metab.2019Feb 5；29(2):285-302.e7.doi:10.1016/j.cmet.2018.10.005.)。也有研究发现在一个模型中，AMPKα1 亚基和α2亚基的缺失使白血病细胞对由营养限制诱导的氧化还原失衡引起的细胞死亡敏感 (参考文献：Saito,Y,Chapple,R.H,Lin,A,Kitano,A,and Nakada,D.AMPK protects leukemia-initiatingcells in myeloid leukemias from metabolic stress in the bone marrow.Cell StemCell.(2015)17,585–596.)。这些结果表明对于这部分依赖于AMPK激酶活化的肿瘤，AMPK是一个极有潜力的治疗靶点。我们的研究也证实了靶向抑制AMPK活性或者利用siRNA敲减AMPK的表达能显著诱导肿瘤细胞凋亡，抑制小鼠移植瘤的进展，证实了靶向AMPK抗肿瘤的可行性。尽管如此，AMPK抑制剂是否能够与HDACi协同增强其抗肿瘤效果，此前尚未见报道。
HDACi在肿瘤治疗过程中极容易发生耐药，因此，临床上需要能够增强其抗肿瘤效果的方案。AMPK是抗肿瘤的潜力靶点之一，本团队研究发现利用抑制剂抑制AMPK活性，能够增强HDACi的抗肿瘤效果。因此，AMPK抑制剂和HDACi的组合应用，有望解决临床耐药、复发的问题。
发明内容
针对上述现有技术中存在的缺陷，本发明的目的在于设计提供AMPK抑制剂联合HDAC 抑制剂在制备肿瘤治疗的药物中的应用。本发明一种靶向AMPK增强HDACi的抗肿瘤作用的策略，主要涉及AMPK抑制剂与HDACi的组合策略及其在抗肿瘤中的应用。
本发明增强HDACi抗肿瘤效果的新方法，主要涉及靶向AMPK的小干扰RNA、抑制剂，作用机理在于降低癌细胞AMPK的表达或者抑制AMPK信号，从而增强癌细胞对HDACi的敏感性。
为了实现上述目的，本发明采用以下技术方案：
AMPK抑制剂联合HDAC抑制剂在制备治疗肿瘤疾病的药物中的应用。
所述的应用，其特征在于所述AMPK抑制剂包括Compound C。
所述的应用，其特征在于所述HDAC抑制剂包括HDAC inhibitor、HDACi、TMP195、TMP269。
所述的应用，其特征在于所述AMPK抑制剂通过基因沉默/编辑技术抑制AMPK的表达，或者利用PROTAC技术靶向降解AMPK蛋白，或者利用小分子药物干扰AMPK中的α、β、γ亚基的组合。
所述的应用，其特征在于所述AMPK抑制剂促进HDAC抑制剂诱导肿瘤细胞死亡。
所述的应用，其特征在于所述肿瘤疾病包括慢性髓性白血病、宫颈癌。
一种抗肿瘤药物组合物，其特征在于包含AMPK抑制剂和HDAC抑制剂。
与现有技术相比，本发明具有以下有益效果：
本发明涉及的AMPK抑制剂与HDAC抑制剂组合物能够显著促进肿瘤细胞死亡，为临床肿瘤治疗提供了新的潜力方案。
附图说明
图1为AMPK抑制剂(CC)与HDAC抑制剂的组合物(CC/TMP195,CC/TMP269)对K562细胞死亡的影响；
图2为AMPK抑制剂(CC)与HDAC抑制剂的组合物(CC/TMP195,CC/TMP269)对HeLa 细胞死亡的影响。
具体实施方式
以下通过具体实施例和附图对本发明作详细说明，以下实施例仅用于说明本发明，而不用于限定本发明的范围。下述实施例，中的试验方法，如无特殊说明，均为常规方法，所用实验材料均为市售产品。
实施例1：
流式细胞术检测AMPK抑制剂(Compound C,CC)与HDAC抑制剂(HDAC inhibitor,HDACi,TMP195,TMP269)组合物对肿瘤细胞死亡的影响。
1.细胞处理
1)慢性髓性白血病细胞系(K562)或宫颈癌细胞系HeLa分别以1×106细胞/孔和2×105细胞/孔的密度接种12孔板中；
2)过夜培养后，加CC(K562:20μM,HeLa:6μM)、TMP195(10μM)、TMP269(10μM)或组合物(CC/TMP195或CC/TMP269,剂量与单用组相同)培养24-36h后，检测细胞死亡情况；
2.流式细胞术分析细胞死亡情况
1)收集细胞悬液,将细胞悬液3200rpm，4℃离心5min，弃掉上清，收集沉淀中的细胞；
2)用预冷的PBS洗涤细胞1次，然后用400μL PI染色液(0.05mg/mL)重悬细胞；
3)4℃避光染色15min；
4)式细胞仪检测凋亡情况：PI阳性的细胞为死亡细胞。
如图1所示，图1A中可看出，AMPK抑制剂Compound C(CC)显著促进了TMP195 HDACi诱导的HeLa细胞死亡。图1B中可看出，AMPK抑制剂Compound C(CC)显著促进了TMP269HDACi诱导的HeLa细胞死亡。如图2所示，图2A中可看出，AMPK抑制剂Compound C (CC)显著促进TMP195 HDACi诱导的K562细胞死亡；图2B中可看出，AMPK抑制剂 Compound C(CC)显著促进TMP269 HDACi诱导的K562细胞死亡。
Claims (7)
1.AMPK抑制剂联合HDAC抑制剂在制备治疗肿瘤疾病的药物中的应用。
2.如权利要求1所述的应用，其特征在于所述AMPK抑制剂包括Compound C。
3.如权利要求1所述的应用，其特征在于所述HDAC抑制剂包括HDAC inhibitor、HDACi、TMP195、TMP269。
4.如权利要求1所述的应用，其特征在于所述AMPK抑制剂通过基因沉默/编辑技术抑制AMPK的表达，或者利用PROTAC技术靶向降解AMPK蛋白，或者利用小分子药物干扰AMPK中的α、β、γ亚基的组合。
5.如权利要求1所述的应用，其特征在于所述AMPK抑制剂促进HDAC抑制剂诱导肿瘤细胞死亡。
6.如权利要求1所述的应用，其特征在于所述肿瘤疾病包括慢性髓性白血病、宫颈癌。
7.一种抗肿瘤药物组合物，其特征在于包含AMPK抑制剂和HDAC抑制剂。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210429195.6A CN116966307A (zh) | 2022-04-22 | 2022-04-22 | Ampk抑制剂联合hdac抑制剂在制备肿瘤治疗的药物中的应用 |
| PCT/CN2022/137379 WO2023202091A1 (zh) | 2022-04-22 | 2022-12-07 | Ampk抑制剂联合hdac抑制剂在制备肿瘤治疗的药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210429195.6A CN116966307A (zh) | 2022-04-22 | 2022-04-22 | Ampk抑制剂联合hdac抑制剂在制备肿瘤治疗的药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116966307A true CN116966307A (zh) | 2023-10-31 |
Family
ID=88419025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210429195.6A Pending CN116966307A (zh) | 2022-04-22 | 2022-04-22 | Ampk抑制剂联合hdac抑制剂在制备肿瘤治疗的药物中的应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN116966307A (zh) |
| WO (1) | WO2023202091A1 (zh) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010056677A1 (en) * | 2008-11-12 | 2010-05-20 | Duke University | Methods of inhibiting cancer cell growth with hdac inhibitors and methods of screening for hdac10 inhibitors |
| MX2020006654A (es) * | 2017-12-22 | 2020-11-06 | Atossa Therapeutics Inc | Métodos intraductales de tratamiento de trastornos de mama. |
| CN110652515A (zh) * | 2018-06-29 | 2020-01-07 | 中国科学院深圳先进技术研究院 | AMPK抑制剂Compound C在治疗肿瘤药物中的应用 |
-
2022
- 2022-04-22 CN CN202210429195.6A patent/CN116966307A/zh active Pending
- 2022-12-07 WO PCT/CN2022/137379 patent/WO2023202091A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023202091A1 (zh) | 2023-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kierans et al. | Regulation of glycolysis by the hypoxia‐inducible factor (HIF): implications for cellular physiology | |
| Marie-Egyptienne et al. | Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia | |
| US20130281525A1 (en) | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | |
| Du et al. | Effects and mechanisms of anti-CD44 monoclonal antibody A3D8 on proliferation and apoptosis of sphere-forming cells with stemness from human ovarian cancer | |
| Hou et al. | Mechanisms controlling the anti-neoplastic functions of FoxO proteins | |
| Jin et al. | lncRNA MIR22HG-derived miR-22-5p enhances the radiosensitivity of hepatocellular carcinoma by increasing histone acetylation through the inhibition of HDAC2 activity | |
| CN111956804B (zh) | Otub1的抑制剂的新应用 | |
| JP7039470B2 (ja) | がんの治療において治療薬として使用するための、モノカルボン酸トランスポーター４（ｍｃｔ４）アンチセンスオリゴヌクレオチド（ａｓｏ）阻害剤 | |
| Zhang et al. | Emodin protects mice against radiation-induced mortality and intestinal injury via inhibition of apoptosis and modulation of p53 | |
| Wang et al. | Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC | |
| CN116966307A (zh) | Ampk抑制剂联合hdac抑制剂在制备肿瘤治疗的药物中的应用 | |
| AU2009271406A1 (en) | Methods for determining sensitivity to aminoflavones | |
| CN106974908A (zh) | 含有hdac抑制剂和ire1抑制剂的药物组合物及用途 | |
| CN115381959A (zh) | 一种治疗肝癌的联合用药 | |
| CN112263578B (zh) | Tipranavir在制备杀伤肿瘤干细胞和肿瘤细胞的癌症治疗药物中的用途 | |
| Xing et al. | Sensitization of suberoylanilide hydroxamic acid (SAHA) on chemoradiation for human cervical cancer cells and its mechanism | |
| Haji et al. | The effect of metformin on the expression of caspase 3, 8, 9 and PARP-1 in human breast cancer cell line T47D | |
| JP2014221752A (ja) | ガン幹細胞に対する分化促進薬及び脳腫瘍治療薬 | |
| Zakic et al. | Redox and metabolic reprogramming in breast cancer and cancer‐associated adipose tissue | |
| Yao-Dong et al. | The anti-neoplastic activities of aloperine in HeLa cervical cancer cells are associated with inhibition of the IL-6-JAK1-STAT3 feedback loop | |
| CN107243079B (zh) | 一种含大黄酸的药物组合物及其在制备抗肿瘤药物中的应用 | |
| CN112933239A (zh) | 激活肿瘤细胞内源性pd-1的试剂在制备抗肿瘤药物中的用途 | |
| CN105769863A (zh) | 替拉那韦在抗癌症药物中的应用及抗癌症药物 | |
| WO2019232156A1 (en) | Methods of treating cancer | |
| CN110859960B (zh) | 靶向AMPK的抑制剂/siRNA与蛋白酶体抑制剂组合在制备抗肿瘤药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |